Eli Lilly and Company

🇺🇸New York Stock Exchange
Back to all articles
Eli Lilly and Company stock analysis LLY overview
Somewhat Bullish +45

Claris Financial LLC Takes $1.01 Million Position in Eli Lilly and ...

📈 Claris Financial LLC acquired a new position in LLY valued at approximately $1,007,000 during the fourth quarter.

📊 Brighton Jones LLC increased its stake by 22.0%, now holding 9,597 shares worth $7,409,000.

📉 HSBC lowered its rating from 'hold' to 'reduce' and cut the target price from $1,070 to $850.

📈 Weiss Ratings downgraded LLY from a 'buy (b)' to a 'buy (b-)' rating in late May.

💰 The company reported Q2 EPS of $8.55, beating analyst estimates of $6.97 by $1.58.

📈 Revenue for the quarter reached $19.80 billion, exceeding expectations of $17.82 billion.

🚀 Quarterly revenue grew 55.5% compared to the same period in the previous year.

🎯 The company provided FY 2026 EPS guidance between $35.50 and $37.00.

💵 A quarterly dividend of $1.73 was paid on June 10th with an annualized yield of 0.6%.

📉 The stock trades at a P/E ratio of 39.03 with a market capitalization of $1.03 trillion.

Bullish Signals
  • Eli Lilly significantly beat earnings expectations, reporting $8.55 EPS versus the consensus estimate of $6.97.
  • Revenue surged to $19.80 billion, surpassing analyst estimates of $17.82 billion by nearly $2 billion.
  • The company demonstrated robust growth with quarterly revenue increasing 55.5% year-over-year.
  • Management provided strong forward guidance for FY 2026, projecting EPS between $35.50 and $37.00.
  • Analysts anticipate the company will post approximately $35.80 EPS for the current year, aligning with or exceeding guidance.
  • The stock maintains a 'Moderate Buy' consensus rating from MarketBeat with an average target price of $1,227.74.
Risk Factors
  • HSBC downgraded the stock from 'hold' to 'reduce' and lowered its target price significantly to $850.
  • Weiss Ratings recently downgraded the stock from a 'buy (b)' to a slightly lower 'buy (b-)' rating.
  • The stock has experienced volatility, trading between a twelve-month low of $623.78 and a high of $1,182.73.
Full Analysis
Claris Financial LLC acquired a new stake in Eli Lilly and Company (LLY) valued at approximately $1.01 million during the fourth quarter, according to recent SEC filings. Several other institutional investors also adjusted their positions, with Brighton Jones LLC increasing holdings by 22.0% and Revolve Wealth Partners LLC adding 2.8% to its stake. Additionally, Schnieders Capital Management, Flow Traders U.S., and Nebula Research & Development established or increased their positions in the stock during the second quarter. Analyst sentiment regarding LLY remains mixed with a consensus 'Moderate Buy' rating and an average target price of $1,227.74. Recent ratings include a downgrade from Weiss Ratings to a 'buy (b-)' and a reduction by HSBC from 'hold' to 'reduce,' which lowered their target price to $850. Conversely, Royal Bank Of Canada restated an 'outperform' rating, UBS Group maintained a 'buy' rating, and Leerink Partners set a target price of $1,119. The stock currently trades with a market cap of $1.03 trillion and a P/E ratio of 39.03. Financially, Eli Lilly reported strong quarterly results ending April 30th, posting $8.55 EPS which significantly beat the consensus estimate of $6.97. Revenue reached $19.80 billion, surpassing estimates of $17.82 billion and representing a 55.5% year-over-year increase. The company has provided FY 2026 guidance ranging between $35.50 and $37.00 EPS, while analysts anticipate earnings of approximately $35.80 for the current year. A quarterly dividend of $1.73 was paid on June 10th to shareholders of record as of May 15th.